Low‐ and High‐Frequency Characterization of Hybrid Acoustofluidic Devices Using Motile Cells

Why It Matters

The ability to map acoustic fields in real time with living microswimmers removes a key barrier to reproducibility and scalability of acoustofluidic technologies, accelerating their adoption in industrial and clinical settings.

Key Takeaways

• Motile algae serve as dynamic acoustic field probes
• Hybrid devices combine surface and bulk acoustic waves
• Real‑time cell distribution maps reveal pressure field patterns
• Identified optimal low and high resonant frequencies improve efficiency
• Method offers rapid, label‑free assessment for clinical translation

Pulse Analysis

Acoustic microfluidics manipulates cells and particles without contact by generating standing or traveling waves. This label‑free approach preserves viability, attracting diagnostics, drug screening, and tissue‑engineering applications. Yet most prototypes lack reproducibility because acoustic pressure fields are hard to measure directly. Conventional methods use inert tracer particles or laser vibrometry, which are time‑consuming, require specialized equipment, and miss dynamic variations during operation. Furthermore, precise field mapping is critical for scaling designs from benchtop to cartridge formats, where acoustic coupling and material heterogeneity can distort wave propagation.

The study uses motile Chlamydomonas reinhardtii algae as living sensors. Cells swim until acoustic radiation forces balance their propulsion, causing accumulation at pressure nodes or antinodes. Imaging cell density yields a real‑time pressure map without fluorescent labels or invasive probes. This captures both low‑frequency surface and high‑frequency bulk wave effects in hybrid devices, allowing rapid identification of resonant frequencies that maximize energy transfer and trapping efficiency. The method also quantifies the relative strength of radiation versus swimming forces, offering insight into device tuning for diverse particle sizes and viscosities.

For manufacturers, the algae‑based method provides a scalable quality‑control tool that can be embedded in production. Real‑time imaging shortens development cycles, improves batch consistency, and supports regulatory compliance by demonstrating biocompatibility under realistic conditions. The technique also enables new research on microorganism‑acoustic interactions, potentially leading to acoustic‑guided drug delivery or cell‑therapy platforms. By reducing reliance on expensive instrumentation, the approach lowers entry barriers for startups and accelerates collaborative validation across academic and industrial partners. As point‑of‑care diagnostics expand, rapid, label‑free characterization will be essential for moving acoustofluidic devices from labs to market.